- Home
- CSBR vs FENC Comparison
CSBR vs FENC Comparison
Compare CSBR & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- FENC
- Stock Information
- Founded
- CSBR 1985
- FENC 1996
- Country
- CSBR United States
- FENC United States
- Employees
- CSBR N/A
- FENC N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- FENC Health Care
- Exchange
- CSBR Nasdaq
- FENC Nasdaq
- Market Cap
- CSBR 135.5M
- FENC 156.9M
- IPO Year
- CSBR 1986
- FENC 2001
- Fundamental
- Price
- CSBR $8.61
- FENC $5.53
- Analyst Decision
- CSBR Strong Buy
- FENC Strong Buy
- Analyst Count
- CSBR 1
- FENC 2
- Target Price
- CSBR $12.00
- FENC $14.00
- AVG Volume (30 Days)
- CSBR 44.2K
- FENC 126.0K
- Earning Date
- CSBR 03-11-2025
- FENC 05-13-2025
- Dividend Yield
- CSBR N/A
- FENC N/A
- EPS Growth
- CSBR N/A
- FENC N/A
- EPS
- CSBR 0.46
- FENC N/A
- Revenue
- CSBR $58,591,000.00
- FENC $47,538,000.00
- Revenue This Year
- CSBR $14.19
- FENC $2.68
- Revenue Next Year
- CSBR $10.11
- FENC $71.63
- P/E Ratio
- CSBR $18.82
- FENC N/A
- Revenue Growth
- CSBR 19.03
- FENC 123.69
- 52 Week Low
- CSBR $3.60
- FENC $3.96
- 52 Week High
- CSBR $11.99
- FENC $11.29
- Technical
- Relative Strength Index (RSI)
- CSBR 39.31
- FENC 30.64
- Support Level
- CSBR $9.21
- FENC $6.25
- Resistance Level
- CSBR $9.97
- FENC $6.90
- Average True Range (ATR)
- CSBR 0.65
- FENC 0.36
- MACD
- CSBR -0.10
- FENC -0.09
- Stochastic Oscillator
- CSBR 15.74
- FENC 4.20
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.